Angiotech to appeal UK judgment regarding UK patent
Angiotech Pharmaceuticals, Inc. announced that it intends to appeal a UK trial court decision to revoke Angiotech's UK designation of its European Patent No. 0,706,376. The UK trial court ruled that Angiotech's UK Patent lacked inventive step in light of certain prior art in a challenge brought by Conor MedSystems (Conor) filed in February 2005. This Patent, which applies to the UK only, is only one of a number in Angiotech's portfolio of patents protecting its pioneering paclitaxel stent technology, which cover the Boston Scientific TAXUS(TM) stent.
The Angiotech European Patent remains valid and enforceable in the other designated States in Europe, in light of Angiotech's successful defense of the patent at the January 2005 European Patent Office Opposition Division decision which maintained the validity of this Patent, including claims related to stents coated with paclitaxel and a polymeric carrier. The UK decision affects only the UK version of the maintained European Patent.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.